ArticleHealth science reports2025
Immune System-Related Genetic Risk Factors for Inhibitory Antibody Development in Patients With Hemophilia: Reviewing an Old Problem From a New Perspective-A Narrative Review.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Hemophilia A and B are two of the most common bleeding disorders. Genetic risk factors are associated with the development of autoantibodies released in hemophilia patients against alternative factors and are the most important problems associated with the care of these patients. Objective: In this study, we reviewed genetic risk factors related to the immune system in patients with hemophilia A and B who developed inhibitory antibodies against factors 8 or 9. Methods: This study is based on the PubMed database and Google Scholar search engine information (2016-2025) in English using the terms "inhibitors", "inhibitory antibodies", "immune system", and "hemophilia". Results: Studies have shown that multiple genetic factors (CTLA-4, PTPN22, and cytokine polymorphisms) increase the risk of producing an inhibitor against alternative factors (8 and 9) in patients with severe hemophilia. Conclusions: The presence of inhibitory antibodies in patients with severe hemophilia may be associated with immune system-related genetic risk factors, and several studies have shown that in most cases, immune system-related polymorphisms (rs2476601 PTPN22, rs2069812 IL5, and rs1800629 TNF-α) produce autoimmune antibodies or exacerbate them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.